JP2020511114A5 - - Google Patents

Download PDF

Info

Publication number
JP2020511114A5
JP2020511114A5 JP2019530815A JP2019530815A JP2020511114A5 JP 2020511114 A5 JP2020511114 A5 JP 2020511114A5 JP 2019530815 A JP2019530815 A JP 2019530815A JP 2019530815 A JP2019530815 A JP 2019530815A JP 2020511114 A5 JP2020511114 A5 JP 2020511114A5
Authority
JP
Japan
Prior art keywords
adenovirus
acid sequence
amino acid
seq
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019530815A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020511114A (ja
Filing date
Publication date
Priority claimed from GBGB1620968.6A external-priority patent/GB201620968D0/en
Application filed filed Critical
Publication of JP2020511114A publication Critical patent/JP2020511114A/ja
Publication of JP2020511114A5 publication Critical patent/JP2020511114A5/ja
Pending legal-status Critical Current

Links

JP2019530815A 2016-12-09 2017-12-07 アデノウイルスポリヌクレオチド及びポリペプチド Pending JP2020511114A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1620968.6 2016-12-09
GBGB1620968.6A GB201620968D0 (en) 2016-12-09 2016-12-09 Adenovirus polynucleotides and polypeptides
PCT/IB2017/057738 WO2018104911A1 (en) 2016-12-09 2017-12-07 Adenovirus polynucleotides and polypeptides

Publications (2)

Publication Number Publication Date
JP2020511114A JP2020511114A (ja) 2020-04-16
JP2020511114A5 true JP2020511114A5 (https=) 2021-01-21

Family

ID=58222021

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019530815A Pending JP2020511114A (ja) 2016-12-09 2017-12-07 アデノウイルスポリヌクレオチド及びポリペプチド

Country Status (15)

Country Link
US (2) US11414679B2 (https=)
EP (1) EP3551224A1 (https=)
JP (1) JP2020511114A (https=)
KR (1) KR20190092471A (https=)
CN (1) CN110300597A (https=)
AR (1) AR110502A1 (https=)
AU (1) AU2017371944B2 (https=)
BE (1) BE1025029B1 (https=)
BR (1) BR112019010906A2 (https=)
CA (1) CA3045973A1 (https=)
EA (1) EA201991116A1 (https=)
GB (1) GB201620968D0 (https=)
IL (1) IL266942A (https=)
MX (1) MX2019006725A (https=)
WO (1) WO2018104911A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
KR102608590B1 (ko) 2014-09-24 2023-12-01 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양 살상 바이러스 및 이의 사용방법
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
WO2017147269A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
GB201620968D0 (en) * 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
EP3532082A4 (en) 2016-12-12 2020-08-26 Salk Institute for Biological Studies SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES
EP3634449A4 (en) 2017-05-08 2021-03-17 Gritstone Oncology, Inc. ALPHAVIRUS NEOANTIGEN VECTORS
EP3655536A1 (en) * 2017-07-17 2020-05-27 GlaxoSmithKline Biologicals SA Lyssavirus antigen constructs
WO2019076877A1 (en) * 2017-10-16 2019-04-25 Glaxosmithkline Biologicals Sa ADENOVIRAL VECTORS FOR REPLICATION
CN112292449A (zh) 2018-04-09 2021-01-29 萨克生物研究学院 具有增强的复制特性的溶瘤腺病毒组合物
EP3807298A1 (en) * 2018-06-12 2021-04-21 GlaxoSmithKline Biologicals S.A. Adenovirus polynucleotides and polypeptides
EP3833382A1 (en) 2018-08-07 2021-06-16 GlaxoSmithKline Biologicals S.A. Processes and vaccines
EP3897846A1 (en) 2018-12-21 2021-10-27 GlaxoSmithKline Biologicals SA Methods of inducing an immune response
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
US12227754B2 (en) * 2020-04-07 2025-02-18 Lung Biotechnology Pbc Adenoviral expression vector and methods and cell lines for production
CN116438308A (zh) 2020-08-06 2023-07-14 磨石生物公司 多表位疫苗盒
CN119677860A (zh) * 2022-06-22 2025-03-21 阿斯克肋匹奥生物制药公司 基于腺病毒的核酸及其方法
CN121816424A (zh) * 2023-08-11 2026-04-07 拜奥卡德联合股份公司 用于生产基于腺相关病毒(AAV)的载体(变体)的腺病毒E2a基因的修饰的序列

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5240846A (en) 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
JP3723231B2 (ja) 1991-12-23 2005-12-07 ディミナコ アクチェンゲゼルシャフト アジュバント
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
PL181241B1 (pl) 1993-11-17 2001-06-29 Deutsche Om Arzneimittel Gmbh Disacharydy beta(1 6)glukozoaminowe, sposób wytwarzania disacharydu beta(1 6) glukozoaminowego, zawierająca je kompozycja farmaceutyczna i środek immunomodulujący i/lub przeciwnowotworowy oraz szczepionka
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP0931158A1 (en) 1996-09-06 1999-07-28 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
WO1998010087A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
CA2302522C (en) 1997-08-29 2010-08-17 Antigenics Llc Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
WO2000011140A1 (en) 1998-08-20 2000-03-02 The Wistar Institute Of Anatomy And Biology Methods of augmenting mucosal immunity through systemic priming and mucosal boosting
KR100629028B1 (ko) 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
US7291498B2 (en) 2003-06-20 2007-11-06 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
DE602005017743D1 (de) * 2004-01-23 2009-12-31 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
WO2006133911A2 (en) 2005-06-17 2006-12-21 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Hepatitis c virus nucleic acid vaccine
EP1957528B1 (en) 2005-11-30 2012-11-07 University of Copenhagen A nucleotide vaccine
WO2008114149A2 (en) 2007-03-21 2008-09-25 Id Biomedical Corporation Of Quebec Chimeric antigens
CN102131920B (zh) * 2007-11-28 2013-11-06 宾夕法尼亚大学托管会 猿猴亚家族C腺病毒SAdV-40、-31和-34及其应用
EP3552622A3 (en) 2008-11-21 2019-12-04 Københavns Universitet (University Of Copenhagen) Priming of an immune response
PL2391638T3 (pl) 2009-02-02 2018-11-30 Glaxosmithkline Biologicals Sa Sekwencje nukleotydowe i aminokwasowe małpiego adenowirusa, zawierające je wektory i ich zastosowania
WO2012089231A1 (en) 2010-12-30 2012-07-05 Okairòs Ag Paramyxovirus vaccines
US8865881B2 (en) 2011-02-22 2014-10-21 California Institute Of Technology Delivery of proteins using adeno-associated virus (AAV) vectors
BR112017026523A2 (pt) 2015-06-12 2018-08-14 Glaxosmithkline Biologicals Sa vetor recombinante, adenovírus recombinante, composição, uso de um vetor recombinante, de um adenovírus recombinante ou de uma composição, método para induzir uma resposta imune em um indivíduo, e, polinucleotídeo isolado.
GB201620968D0 (en) * 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides

Similar Documents

Publication Publication Date Title
JP2020511114A5 (https=)
JP2018524977A5 (https=)
JP7274222B2 (ja) 非ヒト大型類人猿アデノウイルスの核酸配列及びアミノ酸配列、それを含有するベクター、並びにその使用
JP2020511940A5 (https=)
AU737780B2 (en) Methods and reagents for vaccination which generate a CD8 T cell immune response
JP6873054B2 (ja) アデノウイルスポリヌクレオチド及びポリペプチド
JP7630466B2 (ja) 抗原がインバリアント鎖(cd74)の小断片と連結された融合ペプチド
JP7274223B2 (ja) マイクロサテライト不安定性(msi)癌の予防及び治療のための共通腫瘍ネオアンチゲンをベースとした万能ワクチン
JP2018523980A5 (https=)
JP2012516679A5 (https=)
JP2021526831A (ja) アデノウイルスポリヌクレオチド及びポリペプチド
CN118308379A (zh) 爱泼斯坦-巴尔病毒抗原构建体
TWI901715B (zh) 大猩猩腺病毒核酸及胺基酸序列,包含彼之載體,及其用途
HK40031047B (en) Non human great apes adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
HK40031047A (en) Non human great apes adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
AU775973B2 (en) Methods and reagents for vaccination which generate a CD8 T cell immune response
AU2004203141B2 (en) Methods and reagents for vaccination which generate CD8 T cell immune response
NZ759892B2 (en) Non human great apes adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof